Pursuant to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements), 2015 (‘Listing Regulations’), DMCC Speciality Chemicals has informed that the Board of Directors of the Company at its meeting held today on August 07, 2025: 1. Considered and approved the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2025, along with the Limited Review Reports thereon issued by the Statutory Auditors of the Company; 2. Re-appointed Dr. (Mrs.) Janaki Ashwin Patwardhan (DIN: 09180182) as a Non-Executive Independent Director of the Company for a second term of five consecutive years commencing from May 21, 2026, till May 20, 2031 not liable to retire by rotation, subject to necessary approvals including consent of shareholder at the ensuing Annual General Meeting of the Company. Dr. (Mrs.) Janaki Ashwin Patwardhan is not debarred from holding the office of Director by virtue of any SEBI order or any other authority. The brief particulars required to be furnished pursuant to Regulation 30 of the Listing Regulations read with the SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 in respect of reappointment of Dr. (Mrs.) Janaki Ashwin Patwardhan (DIN: 09180182), is enclosed as Annexure I. The Meeting of the Board of Directors commenced at 12:15 pm (IST) and concluded at 3:50 pm (IST). The aforesaid results are also being made available on the Company's website at www.dmcc.com.
The above information is a part of company’s filings submitted to BSE.
